Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2005

View Archived Issues

NXL-101 found effective against multidrug resistant S. aureus strains

AQ4N shows preclinical promise for ALL

DZ-697b: antithrombotic activity presented

Critical Therapeutics cleared for phase I/II study of intravenous zileuton

Dosing begins in new phase Ib study of DOV-21947

First phase III trial begins for HCT-3012 in osteoarthritis of the knee

Novartis selects preclinical development candidate in Vernalis collaboration

IND filed for PulmoLAR for PAH

Nabi Biopharmaceuticals closes operations in Europe

Fast track designation for C1-INH in hereditary angioedema

Memory signs agreement for development of MEM-1003 for bipolar disorder

XL-999 enters phase II development

Novelix licenses cancer therapeutics from the U. of Southern California

Positive results of synDNA hepatitis B vaccine study

Callisto looks back on 2005 achievements

CuraGen and Bayer amend terms in metabolic disorder collaboration

Dyax and Debiopharm restructure development agreement for DX-890

New galanin-3 receptor antagonists for depression and anxiety

PKCbeta inhibition with enzastaurin effective treatment for relapsed diffuse large B-cell lymphoma

MEM-1003 is cognitively safe in patients with Alzheimer's disease

Nexavar receives FDA approval for advanced renal cell carcinoma

New data on vicriviroc presented at ICAAC

RWJ-417457: A novel antibacterial in early clinical development

AstraZeneca presents data on oxazolidinone-based antibacterial agents

Compounds demonstrating activity against HIV disclosed in recent patent literature

New agents with potential for the treatment of thrombotic disorders reported

PKC inhibitors for transplant rejection claimed in Novartis patent

KOS-953 alone and with bortezomib investigated in multiple myeloma

AT-101 demonstrates significant preclinical activity in MM, CLL and aggressive lymphoma